Shubhadeep D Sinha, Ghanashyam Biswas, Bala Reddy Bheemareddy, Sreenivasa Chary, Pankaj Thakur, Minish Jain, Tanveer Maksud, Suraj Pawar, Koushik Chatterjee, Murali Krishna Voonna, Anil Goel, Krishna Chaitanya Puligundla, Kuntegowdanahalli Chinnagiriyappa Lakshmaiah, Leela Talluri, Ramya Vattipalli, Sheejith Kakkunnath
OBJECTIVE: The aim of this study was to evaluate the post-marketing safety, tolerability, immunogenicity and efficacy of Bevacizumab (manufactured by Hetero Biopharma) in a broader population of patients with solid tumors. PATIENTS AND METHODS: This phase IV, prospective, multi-centric clinical study was carried out in Indian patients with solid malignancies (metastatic colorectal cancer, non-squamous non-small-cell lung cancer, metastatic renal cell carcinoma) treated with Bevacizumab between April 2018 and July 2019...
2023: Cancer Informatics